|Table of Contents|

Efficacy and safety analysis of PD-1 inhibitor in the treatment of elderly cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 19
Page:
3663-3667
Research Field:
Publishing date:

Info

Title:
Efficacy and safety analysis of PD-1 inhibitor in the treatment of elderly cancer patients
Author(s):
FANG Leping1; DONG Zhen2; XU Juqing1; XU Wei1; WANG Lin1
1.Department of Hematology and Oncology，Jiangsu Province Geriatric Hospital，Jiangsu Nanjing 210029，China;2.Department of Radiotherapy，the Affiliated BenQ Hospital of Nanjing Medical University，Jiangsu Nanjing 210029，China.
Keywords:
the aged; tumor; PD-1 inhibitor; effectiveness; safety
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.19.025
Abstract:
Objective:To investigate the efficacy and safety of programmed death receptor-1(PD-1) inhibitor in elderly patients with inoperable tumors in the "real world".Methods:Medical records of cancer patients who received PD-1 inhibitor in our hospital from January 2019 to July 2022 were retrospectively analyzed.Patients were divided into middle-aged and young age group（＜65 years old） and elderly age group(65~74 years old was the young elderly group,and ≥75 years old was the general elderly group) with 65 years as the cut-off point.Objective response rate（ORR)，disease control rate（DCR)，progression-free survival（PFS)，overall survival（OS)，and immune-related adverse events(irAEs) of patients in different age groups were analyzed.Results:A total of 46 young patients，45 young elderly patients，and 38 general elderly patients were included in this study，with ORR of 32.6%，31.1%，39.5%and DCR of 69.6%，73.3%，76.3%，respectively，with no statistical difference.In the lung cancer subgroup，the ORR of three groups were 42.9%，43.8% and 47.4%，and DCR were 78.6%，87.5%，89.5%，respectively，with no statistically significant difference.In the general population，the median PFS of the three groups were 12.86，8.90，10.49 months，and the median OS were 19.15，16.30，13.71 months.In the lung cancer subgroup，the median PFS were 22.87，10.53，15.25 months，and the median OS was 29.22，20.56，16.57 months.There were no statistical differences in PFS and OS among the three groups.There was no significant difference in the incidence and severity of irAEs among the three groups.In addition，in lung cancer population，the occurrence of irAEs was a risk factor for OS.Conclusion:The efficacy and safety of PD-1 inhibitors in elderly patients are similar to those in young patients，but further prospective studies with large samples are needed to clarify the effect of immunotherapy on elder cancer patients.

References:

［1］XIA L，LIU Y，WANG Y.PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer：Current status and future directions［J］.Oncologist，2019，24(Suppl 1)：S31-S41.
［2］KEENAN TE，TOLANNEY SM.Role of immunotherapy in triple-negative breast cancer［J］.J Natl Compr Canc Netw，2020，18(4)：479-489.
［3］CARLINO MS，LARKIN J，LONG GV.Immune checkpoint inhibitors in melanoma［J］.Lancet，2021，398(10304)：1002-1014.
［4］SMITH BD，SMITH GL，HURRIA A，et al.Future of cancer incidence in the United States：Burdens upon an aging，changing nation［J］.J Clin Oncol，2009，27(17)：2758-2765.
［5］RAMOS-CASALS M，BRAHMER JR，CALLAHAN MK，et al.Immune-related adverse events of checkpoint inhibitors［J］.Nat Rev Dis Primers，2020，6(1)：38.
［6］NALTET C，BESSE B.Immune checkpoint inhibitors in elderly patients treated for a lung cancer：A narrative review［J］.Transl Lung Cancer Res，2021，10(6)：3014-3028.
［7］SHIOTSU S，YOSHIMURA A，YAMADA T，et al.Pembrolizumab monotherapy for untreated PD-L1-positive non-small cell lung cancer in the elderly or those with poor performance status：A prospective observational study［J］.Front Oncol，2022，12：904644.
［8］SATTAR J，KARTOLO A，HOPMAN WM，et al.The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population［J］.J Geriatr Oncol，2019，10(3)：411-414.
［9］BEN-BETZALEL G，STEINBERG-SILMAN Y，STOFF R，et al.Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients［J］.Eur J Cancer，2019，108：61-68.
［10］占美，吴斌，陈昭燕，等.程序性细胞死亡蛋白-1抑制剂用于老年晚期非小细胞肺癌患者的文献分析［J］.医药导报,2021，40(3)：330-335. ZHAN M,WU B,CHEN ZY，et al.Literature analvsis of PD-1 inhibitors in elderly patients with advanced non-small cell lung cancer［J］.Herald of Medicine,2021，40(3)：330-335.
［11］LICHTENSTEIN MRL，NIPP RD，MUZIKANSKY A，et al.Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer［J］.J Thorac Oncol，2019，14(3)：547-552.
［12］SAKAKIDA T，ISHIKAWA T，UCHINO J，et al.Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies［J］.Oncol Lett，2020，20(4)：14.
［13］MUCHNIK E，LOH KP，STRAWDERMAN M，et al.Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer［J］.J Am Geriatr Soc，2019，67(5)：905-912.
［14］LUCIANI A，MARRA A，TOSCHI L，et al.Efficacy and safety of anti-PD-1 immunotherapy in patients aged ≥75 years with non-small-cell lung cancer（NSCLC)：An Italian，multicenter，retrospective study［J］.Clin Lung Cancer，2020，21(6)：e567-e571.
［15］ZHU W，GENG Q，PENG H，et al.Efficacy and safety of low-dose nab-paclitaxel plus tislelizumab in elderly patients with previously treated metastatic non-small cell lung cancer［J］.Front Oncol，2022，12：802467.
［16］PAWELEC G.Does patient age influence anti-cancer immunity［J］.Semin Immunopathol，2019，41(1)：125-131.
［17］NARDONE V，GIANNICOLA R，GIANNARELLI D，et al.Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a PD-1 immune checkpoint blockade：A real-world retrospective multi-institutional analysis［J］.Life（Basel)，2021，11(11):1235.
［18］韩玉坤，高春晓，童金莲，等.肿瘤相关免疫功能评价指标的增龄研究［J］.中华老年医学杂志,2021，40(9)：1130-1136. HAN YK,GAO CX,TONG JL,et al.A study of aging characteristics of evaluation indicators system for tumor-related human immune function［J］.Chinese Journal of Geriatrics，2021，40(9)：1130-1136.
［19］KUGEL CH，DOUGLASS SM，WEBSTER MR，et al.Age correlates with response to anti-PD1，reflecting age-related differences in intratumoral effector and regulatory T-cell populations［J］.Clin Cancer Res，2018，24(21)：5347-5356.
［20］陆懿，王德强，应乐倩，等.老年胃癌的免疫相关多组学分子特征［J］.临床肿瘤学杂志,2022，27(6)：514-521. LU Y,WANG DQ,YING LQ,et al.Multiomic molecular features associated with immunity in elderly patients with gastric cancer［J］.Chinese Clinical Oncology，2022，27(6)：514-521.
［21］ZHANG QJ，LUAN JC，SONG LB，et al.Age-related differences in molecular profiles for immune checkpoint blockade therapy［J］.Front Immunol，2021，12：657575.

Memo

Memo:
江苏省老年健康科研项目（编号：LR2021007）
Last Update: 2023-08-31